Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
BACKGROUND
We analyzed concentrations of osteopontin (OPN) in patients with pancreatic ductal adenocarcinoma (PDAC) in order to determine firstly whether it is useful to distinguish between PDAC patients and those with chronic non-hereditary pancreatitis (CP) and type 2 diabetes mellitus (T2DM), and secondly whether OPN concentrations depend on the PDAC stage.


METHODS
Groups consisting of 64 patients with PDAC, 71 with CP, 67 with T2DM and 48 healthy controls (CON) were enrolled in the study. Controls were compared with regard to levels of OPN, oxidative stress markers, conventional tumor markers and other biochemical parameters.


RESULTS
Levels of OPN were higher in patients with PDAC compared with CP patients (P< 0.001), T2DM (P< 0.001) and CON (P< 0.001). There were increased OPN levels in CP patients in comparison with T2DM (P< 0.001) and CON (P< 0.001). Patients with PDAC in stage IV had higher OPN levels than PDAC patients in stage III (P< 0.01). There was no difference in OPN levels of PDAC patients in stage III compared to patients in stage II.


CONCLUSIONS
Our pilot study demonstrates the usefulness of estimating OPN levels to differentiate between pancreatic cancer and chronic pancreatitis. Higher OPN levels over 102 ng/ml could be a potential diagnostic biomarker for pancreatic cancer.
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Jana
J
Rychlíková
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Marek
M
Vecka
Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine Charles University in Prague, Prague, Czech Republic.
Marie
M
Jáchymová
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Jaroslav
J
Macášek
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Petr
P
Hrabák
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Miroslav
M
Zeman
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Lucie
L
Vávrová
3rd Department of Internal Medicine, First Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic.
Jan
J
Řoupal
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Tomáš
T
Krechler
4th Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Aleš
A
Ák
D000368:Aged; D015415:Biomarkers; D014408:Biomarkers, Tumor; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000175:diagnosis; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D050500:Pancreatitis, Chronic / Q000097:blood* / Q000175:diagnosis*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D053495:Osteopontin
Osteopontin; chronic non-hereditary pancreatitis; pancreatic ductal adenocarcinoma; type 2 diabetes mellitus